0001113148-20-000027.txt : 20200730
0001113148-20-000027.hdr.sgml : 20200730
20200730190313
ACCESSION NUMBER:0001113148-20-000027
CONFORMED SUBMISSION TYPE:8-K
PUBLIC DOCUMENT COUNT:16
CONFORMED PERIOD OF REPORT:20200730
ITEM INFORMATION:Results of Operations and Financial Condition
ITEM INFORMATION:Financial Statements and Exhibits
FILED AS OF DATE:20200730
DATE AS OF CHANGE:20200730
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME:INFINITY PHARMACEUTICALS, INC.
CENTRAL INDEX KEY:0001113148
STANDARD INDUSTRIAL CLASSIFICATION:PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER:330655706
STATE OF INCORPORATION:DE
FISCAL YEAR END:1231
FILING VALUES:
FORM TYPE:8-K
SEC ACT:1934 Act
SEC FILE NUMBER:000-31141
FILM NUMBER:201061759
BUSINESS ADDRESS:
STREET 1:1100 MASSACHUSETTS AVENUE
STREET 2:FLOOR 4
CITY:CAMBRIDGE
STATE:MA
ZIP:02138
BUSINESS PHONE:6174531000
MAIL ADDRESS:
STREET 1:1100 MASSACHUSETTS AVENUE
STREET 2:FLOOR 4
CITY:CAMBRIDGE
STATE:MA
ZIP:02138
FORMER COMPANY:
FORMER CONFORMED NAME:INFINITY PHARMACEUTICALS, INC./NEW/
DATE OF NAME CHANGE:20060913
FORMER COMPANY:
FORMER CONFORMED NAME:DISCOVERY PARTNERS INTERNATIONAL INC
DATE OF NAME CHANGE:20000428
8-K
1
infi-20200730.htm
8-K
infi-20200730
FALSE000111314800011131482020-07-302020-07-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 30, 2020
Infinity Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware000-3114133-0655706
(State or other jurisdiction
of incorporation)(Commission File Number)(IRS Employer
Identification No.)
1100 Massachusetts Avenue, Floor 4, Cambridge, MA02138
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (617) 453-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of ClassTrading SymbolName of Exchange on Which Registered
Common Stock, $0.001 par valueINFINasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.¨
Item 2.02. Results of Operations and Financial Condition.
On July 30, 2020, Infinity Pharmaceuticals, Inc. (the "Company") issued a press release announcing its results for the quarter ended June 30, 2020 and will conduct a previously announced, publicly available conference call to discuss those results. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained on the websites referenced in the press release is not incorporated herein.
This information and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) The following exhibit is included in this report:
Exhibit No.Description
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INFINITY PHARMACEUTICALS, INC.
Date: July 30, 2020By:/s/ Seth A. Tasker
Seth A. Tasker
Chief Business Officer
EX-99.1
2
pressrelease2020q210q.htm
EX-99.1
Document
Exhibit 99.1
Infinity Pharmaceuticals Provides Company Update and Second Quarter 2020 Financial Results
– MARIO-275 Dose Reduction Effective in Reducing Liver Enzyme Elevations. Interim Efficacy Analysis
Expected by Year End. –
– Encouraging Early Clinical Activity in MARIO-3 Front-Line Triple Negative Breast Cancer Cohort to
be Presented by Year End –
– Cash Runway into 2H2021 –
CAMBRIDGE, Mass., July 30, 2020 /Business Wire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2020 financial results and provided an update on the company, including its second quarter progress with eganelisib (also known as IPI-549), the company’s first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibition.
“We have made important clinical progress this quarter including the generation of early, but encouraging signals of clinical activity in the triple negative breast cancer cohort of MARIO-3,” said Adelene Perkins, Chief Executive Officer and Chair of Infinity Pharmaceuticals. “While these data are preliminary, we are excited by the potential to bring eganelisib to the front-line setting for the deadliest form of breast cancer and plan to present these data later this year.”
Ms. Perkins continued, “We are also pleased that the dose reduction implemented for MARIO-275 from 40mg QD to 30mg QD has enabled the continued treatment of patients previously enrolled in the study. We will conduct an interim efficacy analysis on these patients by the end of the year which will inform next steps.”
Key Q2 2020 Updates:
Clinical and Regulatory:
•MARIO-275: MARIO-275 is the company’s ongoing controlled, randomized Phase 2 study evaluating eganelisib in combination with Opdivo®in platinum-refractory, I/O naïve patients with advanced urothelial cancer (aUC), in collaboration with Bristol Myers Squibb, or BMS.
◦Infinity implemented a dose reduction from 40mg QD to 30mg QD which has reduced the reversible liver enzyme elevations which were reported at the first scheduled MARIO-275 Independent Data Monitoring Committee (IDMC) meeting. Infinity will continue treatment of the currently enrolled patients and conduct an interim efficacy analysis by the end of the year which will inform next steps.
•MARIO-3: MARIO-3 is the company’songoing Phase 2 study in collaboration with Roche/Genentech to evaluate eganelisib in novel triple combination in the front-line setting with Tecentriq®and Abraxane®in triple negative breast cancer (TNBC) and with Tecentriq and Avastin®in renal cell cancer (RCC).
◦Early, encouraging clinical activity has been observed in the TNBC cohort of MARIO-3. Infinity plans to present these initial clinical data later this year.
◦The majority of identified sites are up and running. Infinity has observed an increase in site initiation and patient screening, and Infinity is working closely with the CRO on enrollment initiatives.
◦Enrollment completion is expected in the RCC cohort by the end of 2020 and the TNBC cohort by the end of Q1 2021.
•MARIO-1: Infinityplans to share clinical and translational data from MARIO-1 later this year.
•Arcus Collaboration: A Phase 1b collaboration study with Arcus Biosciences, which is being conducted by Arcus, is evaluating a checkpoint-inhibitor free, novel triple-combination regimen of eganelisib + AB928 (dual adenosine receptor antagonist) + Doxil®in up to approximately 40 advanced TNBC patients.
•COVID-19 Impact: As the situation with COVID-19 continues to evolve, the company is diligently evaluating impacts on enrollment, site initiations, patient treatment and protocol compliance. Infinity continues to work closely with trial sites to support the continued treatment of patients in compliance with study protocols and is proactively working to mitigate disruptions to enrollment and trial timelines.
Corporate:
•Dr. Brian Schwartz joined Infinity in a consulting Chief Physicianrole in April. He is actively providing guidance and insight across Infinity’s clinical programs, leveraging his deep experience in clinical development, particularly in oncology.Dr. Schwartz brings an impressive track record of experience and success, most recently serving as Chief Medical Officer at ArQule up until its acquisition by Merck. Dr. Schwartz is providing guidance and insight across Infinity’s clinical programs, leveraging his deep experience in clinical development, particularly in oncology.
Second Quarter 2020 Financial Results:
•At June 30, 2020, Infinity had total cash, cash equivalents and available-for-sale securities of $42.7 million, compared to $50.3 million at March 31, 2020.
•Research and development expense for the second quarter of 2020 was $6.1 million, compared to $6.1 million for the same period in 2019.
•General and administrative expense was $2.9 million for the second quarter of 2020, compared to $3.8 million for the same period in 2019. The decrease is primarily related to a decrease in consulting and stock compensation.
•Net loss for the second quarter of 2020 was $9.5 million, or a basic and diluted loss per common share of $0.16, compared to a net loss of $10.5 million, or a basic and diluted loss per common share of $0.18 for the same period in 2019.
2020 Financial Outlook:
Net Loss: Infinity expects net loss for 2020 to range from $35 million to $45 million.
Cash and Investments: Infinity expects to end 2020 with a year-end cash, cash equivalents and available-for-sale securities balance ranging from $20 million to $30 million.
Cash Runway: Based on its current operational plans, Infinity expects that its existing cash, cash equivalents and available-for-sale securities, will be adequate to satisfy the company's capital needs into 2H2021. Infinity's financial guidance does not include potential additional funding or business development activities, a potential $5 million milestone payment from BVF based on PellePharm’s ongoing Phase 3 clinical trial of patidegib topical gel in Gorlin Syndrome, or any milestones from, or the sale of the company’s equity interest in, PellePharm.
Conference Call Information
Infinity will host a conference call today, July 30, 2020, at 4:30 p.m. ET to discuss these financial results and company updates. A live webcast of the conference call can be accessed in the "Investors/Media" section of Infinity's website at www.infi.com. To participate in the conference call, please dial (877) 316-5293 (domestic) and (631) 291-4526 (international) five minutes prior to start time. The conference ID number is 7893533. An archived version of the webcast will be available on Infinity's website for 30 days.
About Infinity and Eganelisib
Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing eganelisib, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-275 is a global, randomized, controlled combination study of eganelisib combined with Opdivo®in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq®and Abraxane®in front-line TNBC and in combination with Tecentriq and Avastin®in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus AB928 (dual adenosine receptor antagonist) plus Doxil®in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding: the therapeutic potential of eganelisib; plans to present data; planned analyses in MARIO-275; clinical trial enrollment projections; the impact of the COVID-19 pandemic on the company’s clinical studies, business operations and financial guidance; the timing of further clinical trial updates from the company; the company’s guidance with respect to net loss, cash and cash equivalents and cash runway; and the company's ability to execute on its strategic plans. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that eganelisib will successfully complete necessary preclinical and clinical development phases. Further, there can be no guarantee that any positive developments in Infinity's product portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the cost, timing and results of clinical trials and other development activities that may be delayed or disrupted by the COVID-19 pandemic or otherwise; the outcome of the company’s risk/benefit review of its MARIO-275 clinical trial; the content and timing of decisions made by the U.S. FDA and other regulatory authorities; Infinity's ability to obtain and maintain requisite regulatory approvals; unplanned cash requirements and expenditures; development of agents by Infinity's competitors for diseases in which Infinity is currently developing or intends to develop eganelisib; and Infinity's ability to obtain, maintain and enforce patent and other intellectual property protection for eganelisib. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included in Infinity's annual report and quarterly reports filed with the Securities and Exchange Commission (SEC), and in other filings that Infinity makes with the SEC, available through the company’s website at www.infi.com. Any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity does not undertake and expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Opdivo®is a registered trademark of Bristol-Myers Squibb.
Tecentriq®and Avastin®are registered trademarks of Roche.
Abraxane®is a registered trademark of Celgene.
Doxil®is a registered trademark of Janssen Products.
Copiktra®is a registered trademark of Verastem, Inc.
INFINITY PHARMACEUTICALS, INC.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
June 30, 2020December 31, 2019
Cash, cash equivalents and available-for-sale securities$42,730$42,444
Other current assets2,0642,137
Property and equipment, net1,9512,186
Other long-term assets1,9112,247
Total assets$48,656$49,014
Accounts payable and accrued expenses$8,877$9,698
Liability related to sale of future royalties, net128,72129,626
Liability related to sale of future royalties to a related party, net220,366—
Operating lease liability, less current portion1,6881,926
Long-term liabilities38838
Total stockholders’ equity (deficit)(11,384)7,726
Total liabilities and stockholders’ equity (deficit)$48,656$49,014
1In the first quarter of 2019, Infinity recognized $30.0 million in gross cash proceeds received from the HealthCare Royalty Partners III, L.P. (HCR) agreement as a liability on the balance sheet in accordance with accounting guidance for royalty monetization. While recognized as a liability, the Company is not obligated to repay the $30.0 million from HCR.
2In the first quarter of 2020, Infinity recognized $20.0 million in gross cash proceeds received from the Biotech Value Fund Partners, L.P. (BVF) funding agreement as a liability on the balance sheet in accordance with accounting guidance for royalty monetization. While recognized as a liability, the Company is not obligated to repay the $20.0 million from BVF.
INFINITY PHARMACEUTICALS, INC.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
(unaudited)
Three Months Ended June 30,Six Months Ended June 30,
2020201920202019
Collaboration revenue$—$—$—$2,000
Royalty revenue360257788399
Total revenues3602577882,399
Operating expenses:
Research and development6,1256,07613,47011,842
General and administrative2,9373,7716,2617,169
Royalty expense12171554756,916
Total operating expenses9,27910,00220,20625,927
Loss from operations(8,919)(9,745)(19,418)(23,528)
Other income (expense):
Investment and other income50318235607
Interest expense(39)(1,087)(77)(1,391)
Related party interest expense2(565)—(1,099)—
Total other expense(554)(769)(941)(784)
Loss before income taxes(9,473)(10,514)(20,359)(24,312)
Income taxes benefit———54
Net loss$(9,473)$(10,514)$(20,359)$(24,258)
Basic and diluted loss per common share:$(0.16)$(0.18)$(0.35)$(0.43)
Basic and diluted weighted average number of common shares outstanding:57,442,32256,942,03357,392,96556,933,521
1In the first quarter of 2019, Infinity recognized $6.7 million of royalty expense, which reflects Takeda’s share of the $30.0 million gross proceeds received from HCR for the monetization of Copiktra royalties.
2In the first quarter of 2020, Infinity recognized $20.0 million in gross cash proceeds received from the BVF funding agreement as a liability that will be amortized using the effective interest method over the life of the arrangement, in accordance with accounting guidance for royalty monetization.
Contact
Ashley Robinson
LifeSci Advisors, LLC
617-775-5956
arr@lifesciadvisors.com
EX-101.SCH
3
infi-20200730.xsd
XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
0001001 - Document - Cover
link:presentationLink
link:calculationLink
link:definitionLink
EX-101.CAL
4
infi-20200730_cal.xml
XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
EX-101.DEF
5
infi-20200730_def.xml
XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
EX-101.LAB
6
infi-20200730_lab.xml
XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
Written Communications
Written Communications
Pre-commencement Tender Offer
Pre-commencement Tender Offer
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Entity Address, City or Town
Entity Address, City or Town
Soliciting Material
Soliciting Material
Entity Address, Address Line One
Entity Address, Address Line One
Security Exchange Name
Security Exchange Name
Entity Address, Address Line Two
Entity Address, Address Line Two
City Area Code
City Area Code
Cover [Abstract]
Entity Central Index Key
Entity Central Index Key
Entity Tax Identification Number
Entity Tax Identification Number
Entity File Number
Entity File Number
Document Type
Document Type
Entity Emerging Growth Company
Entity Emerging Growth Company
Title of 12(b) Security
Title of 12(b) Security
Amendment Flag
Amendment Flag
Local Phone Number
Local Phone Number
Entity Address, State or Province
Entity Address, State or Province
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Trading Symbol
Trading Symbol
Pre-commencement Issuer Tender Offer
Pre-commencement Issuer Tender Offer
Document Period End Date
Document Period End Date
Entity Registrant Name
Entity Registrant Name
EX-101.PRE
7
infi-20200730_pre.xml
XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
GRAPHIC
8
headera0311.jpg
GRAPHIC
begin 644 headera0311.jpg
M_]C_X 02D9)1@ ! $ 8 !@ #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$ (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @,# @(# @(" P0# P,#! 0$ @,$! 0$! ,$! ,! @(" @(" @(" @,"
M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# __$ :( $% 0$! 0$! ! @,$!08'" D*"P$ P$!
M 0$! 0$! 0 $" P0%!@H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q+CY.7FY^CIZO'R\_3U]O?X^?H1 (! @0$ P0'!00$ $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_ !$( %8"MP,!$0 "$0$#$0'_V@ ,
M P$ A$#$0 _ /W\Z?A_2@#RCXS?&/P=\#/ FI>/?&MQ=)IMD\5I96.GVYNM
M3UC5;I9?L6E:?;Y53/+Y4CEY)(XXXX99)'5(V-=6$PE7%UHTJ:TNN:6GNQYD
MG*SKC&32UU:3TO9VVM?H?E/K'_!6K5X[Z;^Q?@E:I
MIJX,!UGQ;,;]E&*?^B,: ,>OBS41C'UT>NW_5&/_0:__!2_^6&7
M]MR7_+BUO[__ -H36W_!6CQC>7-O9VGP2T2XNKJ:*WMK>#Q3J7_+SHNUWV3"&=SG*-
M.GA^:&M
M2U#Q'XJTH7$<9]1>#/&WA_P =Z2-6
MT"[,\*R>3<6\R>5=VG0ZKKTL
M=;D"H'M\@R!2;4=]+!V_ ,@4E)/9[ ]/(,BG="NA:8PHV^0"9 ]L?AC%*Z5O
M/1!:WR$W#W&/8C]<=/>G^@KK3\!V/PQBC;Y"30FX#U'.!P1S^73WZ4KK[BK-?(76FWR
MI=$]$%F&10OR%:WR%H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H :2 #S@ 'G&<8'I
MCM4J4;I7U;22\^@;*_1'XY?M=?$31?B[XS7P[;ZHDOAGP9)%A%N/+4DTY;;::;O9K\VMSSZSC
M4E;>+T?IK?L^I\;3_#+0;H_(]J^4\O<2PP23Q\T@Z;A^=>LJTHZ_RZ_=\C%X
M:A9I+7I\7^9@W7P8L)=QC6V;;EF[_ /DCZJ^!7P%T+X3V5C\4-6TNWU/Q_KR&'X7:=/"+@>'K-9"E
MUX]>'YE_M/SHY+?2]X A=)[P!BEL]>3CLSJ3_N
MVFMV=$,MI4YPG%:P::WW3NOM>1[E;^!-2O6-UJE^L4\S-)*OSW=P9)&\QGFD
M>11YK,Q+$LY+$LV2QKR9XJCR2Y9^]9V]V6]M-U8]#DDNFWH>J?">[U+X9^+(
M+R6[6[\.:J%T_6T *RVL!O[0_P 1
M?V=_!_@/6?AW-H\%]X@\27^F:@VL:6FJ0FUMM.%S$(HVFC,4GFY^8;N.#7L9
M!@H8VM7AB(W48.45=K:4$G[LH]]F>7F6*>&C247RMM=/*7=/L:/[!_Q^^(/[
M0?PY\7^)_B)/I$^IZ)XUDT*Q.C:8NF6XL$T+1]0"RPAWWR_:+Z8[]W0*,#;\
MV.WE88P.I4E#G XX(_A##KCL1235[=MQ
MVM:^B_0^,?VW/VCM>_9S^%ECK/A.QM+GQ9XKUO\ X1O1;R^1);'12+"[OKK5
MIK1GQ>S11VR1PP,0ADN \FY(FCD]C)SJWY8I-1U2DG*,;-II]=TUK
M;IH_+S'%SPT.:FK+6*E=/WK2:TL^U]4?EY\/_CU_P4C^+>FW_B#X;ZUX@\3Z
M-9ZD^G7-[IGA'X;PV=OJ!BCNC8Q/?:'#O>.WN+=B )"JS1%R?,4M]%B\OR#!
M2]GB+4IV=E_M#VNOLRDM&OE\T>33QF:UHMT%S-;?PEKT^**2W6Y]._M2_%/]
MM'P5#\%+?X:1>/1J>I?"70[_ .(Z^'OA[IWBE!XZ),>K?;Y(O"^H0:?>B57S
M;VS0Q ;2D>PJ:XOFL%0
MA"/[QT8.:_^&>L^/%OO\ A,]4\&Z!?>*#
MJ6GKI5^-:N+"&341>:7':6R:?XI/E?O>]M;1Z]SU*,JZH4?:Z57R8L;%-J[#EMP&!@UM14)5*
M:E;V?-%2W6EU?6]UIV,I\\(2Y86E%-K5/5+31Z;]S\8_V#RJE@O:TH\M:,+MWK:-0;^U)QTDEI;\#R,+B\PEBW3JZ4%)K:E\/
M.E]F/-\-_/YGVG^VA^TUXH_9E\*>#?$'ACP[H/B"?Q'KU[I-U!KKZ@D4$-MI
MXNTDMS87,3>:7X.\D8Z#->9E>7PS*I.CS.,5%.ZMLVHWL[7T>R:9W8W%RPRB
MUI%]?OMI9O9'4_L?_'SQ!^T7\++OQ[XCT32-!O[7QCJWAQ;/1GNVM6MM.T_1
M;R.X8WD\K^71RRNL/"7,I14EI;3FE'O+^2^_4TP>*C
MB*3ES7LW'9K6T7;9=_0^KJ\TZ@Z?A_2@-OD)N'KT^O&*=F@M:WGM^AS7B/4=
M7TZ*PETI-.D6?4K#3[E;_P"U!E&H7UK912P"W^\8S.SLK8R$XYHL^VP^5]MC
MS[P-\5I?&'B,>')-&?3KFUT?4K_4F@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H ^%OV\_VB%^!OPCDTC1[OR/'7Q&^U^']
M!\IHS/IFE)%&OB+7-K E##:7,=I"ZCSP5"JZEU.SA%+7WVFDKWLDF
MFVWT3W=D_1P>(6*FO8RYE&7O:6M9J^Z6UUL?K%\1O![>'/$\M^L9>SO[6TAT
MR4HHBT[3K&%+>#1+1%XM[:T6!=JJ!N#JS$LW'QU2I.5K/1;Z)=7=[+>]SVE'
ME:UM;]#A1R !D[?E7))Q@Y R?<77w m:2l>Q)^;G_ 5I
M_P"2"G/;QIJN/PT8>E?4\)V^N54_\ GU_[?3/GL]T5)[)22^?OGF'[$?C#
M7O /[%7[3'C+PM>KI_B'POK>MZQHUZ]K:WJ6NH6O@[P])!*]I>P2P7"[D *2
MQNI':NG/Z5.IG.!HVYHU%3BUJKIUIJU[IJ][731&73E3R_%5(RLX.HUIU5.+
M6_IV/)OAG_P4R^.NAW?B"7QR]K\2+B[T%M/\'Z%'H>@Z%9V_BFZU+3OLFIZE
M/H&DV][>6D-A%J4?V*&0-/)=0H&BQYT797X;P=54517U:,>5U9^SXL+G.)A.K[6/M'[RIQ]U*]X\K?+%.R5]-W^*V?%'Q3_P""
MG6H6,_CRXT?XC>'M @=]0^P:-X%TJPMK"T5%E(?0I=+FU2;3HXDR7O4N!MW&
M1V+,24L+PQ%K#J5&I-KEO.K)MO;XKJ";[*WDC:=?.FG5Y:D(+6T8))+_ V<
MK>IZ+^R1_P %"?B-K?Q \/?#3XU3V'B&Q\7ZA::#HOBN#3;+2-5TG7=0D2VT
MJ/5(=-@MK2^T^YNGC@D<0Q3Q/*)6D=%93Q9IP]1I477P:?[N;E*FKKEIJ,I.
MSG-W?5?!6E^'(9=22&YB7R;W3]'M#=[M-+':[2)M.[[V"/7R
M2AE:4OJTU+$1I)U(KVFZY;ZM\J][2ZT[:(\_,*V+4OWT.6BZEXN\/A]ZS]U7
M^'H]>^I9_9L^('[:7A;P%?6/[/>A>)M2\$R>)+V[O+C2_ .E^)K=/$#:?I4%
MY";[4-&NI8Y5L8-,8VXD "R(X4>9EHS2GDWM.7'6I5G!N*:\F?8W[7?[5_[1OP6C^!EAHGB"+PUKOB
M;X1:)K_CK3]1\*^'KF[_ .$PD8PZJ9H-2TJ7^SWCN(Y8VMH/)C5@PV 8QX^5
MY5@L8L5.%/VU.G6J*'O3C>G%0:6LTU>^[NU?R.W,,7CL,L.O:%?$]I9>*_B-H45WXNOY?#OAZ\CU
M.[?P]IE\SQV-YI\MMIZ_:[B5PMK'"HW[=NQ0HC+LNPF(S',,-5HWC04_9PYY
MKV;C.,4^923ERWMJVI;FV+QN)IY?A*L*GOS]GS>[%7O3;:V:6W1(^?\ PG_P
M4&_:C\;^$].^'G@'P[+XS^+U_J&JW>H>)[+PG8:ABA;6.PM-%\-Z+8QV2
M-;LMQ)/J.H6\B 3HGE_+Y@[O[ R^C.>(QE7V.&A[J@Y\B;NW>4W*3LU9*,6G
MH_GRT\TQKIQH4:?-7EJVHJ32LE91BDM&G=M6V.)\=_'/_@HS\'6@\2?$+5?'
MOAW3KJ2&-+S5?"WA:\\.&977RK622#1;C3K2YD,6/)=HI) 6.TAB3UT:,JF*S?"M3K>T4;K1J/*_[MTFHM[?H?HU
M^Q5^V-JO[16A>*?#_C"QT[3?B+X,T^'5))]*@DM].\0:+-']G75%LY995L[R
MWU 1QW$23!&^V0M"B*66/Y[-,@HX/$X=PE?#5*M.+W6\I>ZKRE)7C&]WL_N7
MHX3-:M:G5@J/+5A3E+XHZ625]8Q3M)[?@?&/[,_[;7[1_P 2/CYX%\!^*/&M
MCJOA_7=1UZVO--A\(^&+22X6S\.:U>64:W=GI5M<1G[7:6S_ "2J=R88E&*G
MU\5DF5T_/5Z0;V]H^W8X2>&Y=6\$Z3X6B?4OLWEW"PW-AI-H]
MX39;2R,S@ DK@\UU9)3RJ,E]12E6C2BYVE5TLXW?OMQ=I=M^FB8LSK8^,U&O
M2Y*$M(OFIO=RMI%OSU-?]G#XB?ML^%_A_=:=^SWH'B75/ ;^)-1N[BZ
MTCX?:1XGMD\0266EQW\0U&\T:ZD$JVAZGXMMH-*UWPSX7\7:1!?^!O"L9:'4M,M'UK1KISHJRIJ5XO3[,KIG[*?"3XCZ1\6_AKX-^(VBE%LO%6A6>I
M/;K(LG]G7[)Y6JZ7*ZD@S6.I17=H_/WK9J^.Q>&G@\15P\]Z4Y13_F2DTI*W
M>WRV>J/H*%>&(HPJQ=N:*;6NCLFU\KGPU_P4 _:U\4_ 2'P1X/\ A?K.GZ;X
MYUZ:77-8N+C3;'5I=.\,VYELK.-;75+:>U5]0U$7)#F-Y%727"A1*&/LY!E7
MUYUZF(I\U&/-&"YK>\N1_9E%[2TZ;WUL>?F&81P[I4JKS^+=3ED\)6$>AZ+H8L/#VF,]D+Z1=(TZT
M:YEO]12ZD4S;U$-M;R1;1,G;V3:E[TG9QE)?:;VLOP9UX&
MO5K4E.IUVV[1?1+N?8ZP01G='#$C8QN1%5L JDP*TVI0J)'AO/LR/+"JVLA0Q>8\/T?#F8X3#U_J-6IR5ZLN>"Y9
MN[G*G3C&\8M+WENVDO0\'.Z4Y>S<5=+EZK^_W9^'%]8WNGW$MG>VUQ97,#F*
M>UNH);>Y@D'5)H)562%@".&5<5^@I::==CYJ47#1^Z^W_#%>"":9XXH8WE>6
M2..)(T+R2/*56-8E.=[,64 #N>:QJRC1A.55\D(IMO5V23;=E=Z)/8B$)2E&
M$5=R:26F[=DM=C^F[]AW]G>/X!?"&R_M>S6'Q_XX^R^(_&$CQ&*XL/-A5M*\
M-FVTS^:HZW=Y>G)4(%_.*?([TJ-X0?=1E.TK-1:T>SNU;?4^Q
MRW!_5J*ERVG*W,K[:1;UYFMUT/I_QOX<7Q+H5U:I>P1-YQN%Q&K?N5+
M,JKYRGR\M\H)#1HMMLH3/*-J(Q.#)G<54-MP&)Y QGI5)NZ%%J_
MPV[:G2_!G5;K7O'-T]L)#IVEZ;=&Z=4Q"KRLD-M#(S(/G=][KR2?LQ/0'%EH
M^2O^"M7_ "3?X4_]CIJW_IF%?4\*_P"^5?\ KU_[? ^>SW^'3_Z^+\IGA'[*
M?_)@/[7/_7QXC_\ 4+T&NS./^1_E?^*A_P"I$C# ?\BS&?\ <3_TU$\\_P""
M7WA#0?$W[1=]J>L6L5WK^)-"2:-)8[?6&U;0]"BO=DB%1+#9ZS?-$X
M(9)-CJ0R UV<25*E++;4Y.*J5XPG;K'DG+E]+QC>W:VS:.3(X1ECY.4;\D)2
MCY2YHQO\DW_P]C^B>OSX^S/Y@=6L;/2/V]6T[3+:&RL;7]J"VM[>UA15A@MU
M^)$+K!$A!"0J?NH,!1\J@+Q7Z5K/(7+XKX-MMO?_ &>[\]>Y\;%*&9S27+&.
M(E9=DJJ_(_1W_@K'Q\*_A?ST\?70_P#+?O"01WZ#K7S/#:_VJNN7F?L96UM]
MN!Z^;NU&CT3(5 /8+X;\'@ >P K'B"T
M,;27)ROV4>M_^7E2WI8K*-,+4_Z^2_\ 28'R+_P5FX^*_P +/^R>7/OC_BH]
M4)KW^%/=PN(Z+VM1+UY*)Y^=Z5J?3]S'_P!*J&7^V%Q^QO\ L5]./#EMUSCC
MPIHO4 @X^A%9Y/IGN;=+>W_]/P#&Z9;@?)T?_33/L+_@EAX3T+3_ (%>(/&-
MK9QCQ#XE\E7%?\ 8/4_]*@?.'[#
MO'[77PB]O$.N_IX7U^NC--,HETM2?_IF9SX#_D9O_KY_[EB?HU_P5I9D^''P
MJP=O_%::L>, @KHPQ@]1^&*^=X6$?6L>)M,PI^5%?^G:ITY'_ND_*K+_TB
MF;?_ 4(X%BB#7-[X7EB1?%%@A6)I',-O!;
M:DJ!@#_94B@%I14\.8[ZIC51F^6EBK0?937P/[VX_P#;WD5F^%]OAO:17OT+
MR7^'[2^2U^1\L?\ !+?X\6VF6?CGX,^*=3M[+3["VO?B#X5GO)8X4A@MH8E\
M7Z>K,H)2.WAM=35%8E5CU*7&-Q'I\2X*4ZM"O2CK+DI6NOBE*HT[N2MJTK6M
MKOH>7D^+Y/;4JKY5",YI6Z1Y$M4NU]+WT/C3Q-=Z]^VM^UVUOI3S+:>,O%::
M1I#R9N$\/^ =$61&O &6, 0Z!976H/& H:>X=!EY5SZ%-4LKR5RG^ZJNG=+5
MWJ.C>VG-%7E%Z[7]=>>:ECL?'W/=C-*+O]A5--/=>TNNI_3!XYR3R:_/:E:56K4J37O3
MFW?U=[VLK;['UU*E&C3C".G+;3T27=]C;I&@4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '"?$+P@
MGC'PU=:8K>1J4'^GZ-?*S1RV&K6R,;::*6-U:(-N>)V4Y"RD@94$>!Q)E?\
M:N58FC!?[3AZ=2MA7?;$PHU(T'9SA'XI[5&Z?\Z:1R8RE.MAI1@OWJB^75:2
M46ENTMWZ=]$?"EMKL^HWLFA?$'1M \6-IDLNG30>,/#FA>)+F,6UP\3PF[UG
M3[J5E5FF&P2A072"=.ONO0C"ZJ<9(SGWYKXNOXBYS2;4J?+9.WO4'W[89]B*F<8ND[*
M%E?5WAHM4W;DUT6R,_\ X:9\>D "P\,G*]#8:@ W/I7-2\2LU]
MK24HVCS13UI;75]L-V[$PSNIS03DDKI/W5M=?W#*A)*7-))Z6:U2BOY4NIXUXN\7RW$@L;(F2
M2:06\$$0+.\DC&-(E41Y+EG0 =>?2O>5.:>VWH=#ER[JUC[L^$'@0> O!]I8
MW2+_ &YJ*Q:EKTH*N?M\L2XLUD4D&"TC(A7:=I<2R*/WI);36G8:E%=;6/SH
M_P""M )^''PI"\D>--6X&,C&BYZ?13^5?5\)QE+&UE%7#_ +*OR?L!?M;J006N?$048)SGP9H(["NS-XR_MW+)
M)>[&5*[_ ,%=N7W)KUZ7,,"N7+<7%Z-JHTO+V<>QA?\ !*)&3X]^.205'_"I
MM4'Y>+_!V>/09'/N/6M^*%;+J73FKQDO\+IU;/\ X&_D24;^
M?/3=K;G] &0!Z ?7C'L*^!2VM\CZ]^ZF]E']#^8[Q.K?\/ +AA@J?VIK4@@@
M_?\ B/ J\ \'<0,=N]?I%*I"/#_L[VD\+R)6?Q?5K6VMOUV\SX^4)1S-W5O;
M5_O=/RKYWAI\N,K=/W32
M]?:0/5S=/V-&FE[T'%M=K*:>NVGD=G_P2P('[.GB &_!S=#
MTX8?G6'$G^_4FMHTXQ^:J5="LJ7)AZD7[KJ8' YZ=NG&>HS[W"[2P==;6K3E\N2EJ>=G,DZM.STC2C%
M^J=30S/VPE;_ (8Y_8L3:G9^S'@\'_ (6'XK..
MN,VNB8Z=#[=N]>/Q')3QU-Q=U&E%/U52IW/7RB$J>%DI+E?.Y=/AY(:Z7[;;
MGU#^T\&-3/IZ*?RKS]?:9]K'
M-;/$T&NFEJECYC+9Q@\35;M3^KU%>SW]R6RUV5]O+>@!\,:^!D]O3%=&9K_ (2II;QI._RHR,,!)+,(SO:$ZBY7WO5BUINK
MKO;S/TR_X*M>'-:U/X1>!-TNKDH?W-
ML]U"L/FN-HDEACR&F7/S7#5:G1Q53VDN7F@HQT;O)SA962?;?;NUH>[G.&K8
MBC3]C#F]G44Y:Q5HQC.[]YJ]KK1:]D?%G[)/[>6E_LV_#34?A]J?PZO_ !8U
MWXLU'Q+;ZG9>(K;251=1T[2;%[26WFTFZ)\M]*#B0.,^<1M&P%O9S#)O[6Q'
MUBEBE25->R:VW3M&^%KRVN)8);GP-XNM;ZQ-@\ZR[I8EL;G4=&N2Q
ME-M< C:YS^CX'%?VC@J%6JN;V;@IRO;]Y"$>;1*-[FG8^,QJC@L8X4UR1
ME'EMJ[1I
M6PY*+K^'
MY++5(I[/0XX+2X?46NY;%;26!8;ZU8^5:QDTU;US//?6L;:O8/'.OD>:Q21"%^<9T=):
M;;OW?,(8S#3YN2I?DBY/W9*T5:[UCY[;E%?VF_@2_P /H_BHGQ$TMO $NO+X
M7C\0K8ZV8FU]U#II8L1I?VW[28R'YMMNPA]VTYI?V?C/:SH>Q_>TX.I*//#2
M$9-PJBI^UM%RY4^67Q6O:W+?;KMYEVT_:+^"][I/Q UVW
M\=6/]E?"RYCL_']W-IVN6J^&[J6XGM(8+J*YTN.6XD>XMIHU%JD^YDP,Y&9E
M@,7"I2I.E:=:W(N:&M]%JI67S:''%X>2FXU+JFFY>[+1+?IK;RN-E_:.^"D'
MA;P;XT?Q[I[>&?B!K!T#P;J4.GZW(_%'ARY\
M366IVLNEZQ.^@6]E:Z-J307DTEM'I"I@YXQ1
MIN2A3FH.+4HKG;ZLEJ>*_'3]M#P+XPU"R\,M;6E_IWVR2%[\7-E'(^HIM>18MU=V-R_#X=9A&GE56*H07LZOM
MKQ@O>_>M.5VI6NHV;5O,YL+BZU3ZIS8ZFW4D^:'L[-_#[B:C9.-[-Z7N?I_K
MVO:+X6T74_$7B+5++1-"T:SGU#5=5U&XCM;&PLK9"\UQW*O7?A
M?X>?$'3M;U^TCGG72I;+5M'N[ZUM1F>[TN+6M/M#JEO&N69K;S2JJ78*H)KM
MQ65X_!4U5Q&'=.F[+FO&23Z*7*WROULU\4V^I_V+=Q-::NVD6.KB7[.VFWOB./3VTNUNDG!
MBD$EVJQ.K)*R,C!;AD^93H+$PPLG2<>9:QYG'?F4+\S5M=M5L2\PP.?VD_@=\-->U+POXZ^(FC>&]?TG0D\27>EW\6HK/\
MV3*0L$MJ\5D\5]=3,0(K.VDEN9#]R$X.,J&6X[$TXU:&&E4IRGR*2M;F6Z>M
MTEU;LEW+JXW"T)RIU:T83C'F:=]NG37R2U\CSR;]N7]ENW\*V'C"3XJZ;_9.
MHZG=Z1;6\>DZ_)K8O;%+>6[%QX>CTIM1M;:.*[MF^U36R0-YRA)&;('0LCS1
MU945A)CT3OIL9/,\#&FJGMTHR;25IN:?::KI&IV;^9:WVGWT*7%K
C36C7R.V$HSC&6M3Q$(_#)2GK\*3E*6[UMY:OMWX;P[JMNS*S!25Z@@B-% Z#D&OG\!
MBJ>(PD:?FCSC8T;X(*A"1UY
M 7:>"#GCVKY:$)\Z45K%J^W1V]#RW&3^KQBO=3:T3W:BNMM#WQ?
MLS_#V;Q1XFF\R4VJC7-RNZ>NZU3LGY]58^]K_7=$TF6*WU/6-,TV
M:="\,5_?VMI)*BMM+QK<2H67=QD9YX[5/,]G"R>^O3J:V_ S/$/ASP;XK%EI
MWBG0_#7B,)YMYIUCK^FZ9JZJ51(Y[FTMM0AE Q'-&&DC7HZ9."*NFI4KSHR<
M+KE;7\NCMZ:+\C.K3A4BHR5TI72\[->71LS]/\*_#?2O#FI6&F>'/!.F>$]2
M%Q)K%G8Z3H=EX>U!%"VES)J4%O EG=J%@$+M,&&(=CF>%?AGX#+ZYHWAKP+X.\^!;5]8TW2-!\/F>WN'CF6
MV:_MK>#S(9&@BD$9SCI:^EK6V]-/30RE1@VJGLTY
MP::=]FM5Y:,U=;T#P;XO)TGQ%HOASQ,=+DBNCIVM:=IVM#3I;F)D@G^S7T,P
MM))(=VUMJEER1D9J8WI*7LGRRE?\?7I=+38B&[;PKX>F:5[N3P_H<5 m>UU::UNM/DNQI",*:4::Y;:+??YF/XET3X5^(=4@B\8:/X UK6K:..RMHO$N
MG^'=1U2&*=_,BM($U2*2>.*267%O!5_HWA552TTW4M&T*ZTWPZJV\>U8+2ZMVATI
M1:K%]U8_W87^'%)2KQ;DJSO*]]%UW*E3@X1IM^[&UEKT5EZ$M@_P^\#Q/H>F
MMX-\(0+-]MDT>Q?1/#\0FN0F;M]/MS OF2HD?[TQY1TMW'I.L0:AHMXFGZI!/9>3J>DW'V:\BFL-0CEC$5_8R;UDL[F)9D
MV2H4E42+AAN%$93C*+Y>7E:UOM9[Z=B914XN#>DDT].C5MCCO"GAOX7:5>7T
MG@G0/ &GWXM_L>J/X5TOP[:WGV5I 3:W[:1 LA@,T7^KE^4M'TRM;3K5)\O-
M5FU%IJ[D]KVM?:U]+;$4X1I+DCK%:;6[+SZ(71_AU\+=*U87F@^!O >G:[H\
MB2"[TGPUH%IJFF37,,FQQ/9V2SVDDL,DA'S*75R>0"YMIXG#Q
M3!94>-T8'YD*D9%'-.FXNG=2BTTT[-?/H*UTXMZ/1Z?(\*3]GO\ 9>UF_O?)
M^$7P:U/4EEDFOTM_"GA2[N8IC)MD:YAAM&,)\W((95^;/&KT6IF\)A9-'X-&MO#K:5:Q6L=L-(NU,!BU!0BH(E06X0#!^
M7NR[*O[2C*;JN-Y6>G,_LMMMRB[OF_KIS8S'/!M0ITKQ2WYDK?$MN5[**>GH
M?B1XZ\8_$3]M_P#:)TIK72FM-0\476E^&?#NAV[R7=CX4\+VLKM++//((1+;
MVD4VH:A>7)6'S&>[Y=_FY
MUZF.QL%[/F4I1BWS)67/;:T7HF?TO?#SP1HGPT\#^%O 7AV(0:-X3T6PT:RR
M,+.!$FNYMSN?M-S<>;<2G
([71M7MM-NGE\Q0MPESK/AS8496Q;J!D*6Y/!8G!1I
M-V^K8M5FEIRTX1@W+I=:M6UD];+MX6818(_$=]9OO167%DI.&
M4!/2[OHHW3::L[.[T7G.56,L-A8+2=2G.2TV
M?NMW?E;1->5MSZ!_; OS\!?C=\6;71K(0:?\=/V==*\'Z3#"C(J7D>I>'?"\
MT"'[6))I4T#PQ.@53N9[V,.CH"6YL!_MN7JM)\U;#XF59^2A"]^BLG+1:NUM
M&C;$3^J8F4+\L:E+D77WG+1:7MMOHO0\UB\/-I7Q%\/?L6N99--M?VI?"_C:
MZ1DN"LF@7?@W2OML 5;Q7^SQV,D[DX&[S$D#G8*ZO8_NL5F$?A^I58E^A,&Y*A23U]O!M>3LGY?J=C^T,9O 'Q\_:*^"UI&8+/]I36?@K
M=:9L_=Y:[\4V%WJQB)N]T:/J,^NPN54J?,(\L;5*X8&$<7@%BVVI82G+S]ZE
M3T[7NGS7L][-O5%UI_5L1*@W95FX)6WYY66U[7M;=6[]2C\++-M;^/GP7_9C
MFA\K2O@/^T)\9O$LL3Q7)0:)H5[9>(_#Q;S;L-AI]'U:/>8\;+V-D:3Y\QC*
M7L,(\8M%CFKJPE-*VK7-Z)=K=51E>I"D]%AZZJ-=HTVDWYV[)M^3/I'
M_@HO\0?!7Q)_9V\":_X#\2:9XIT6V^.VDZ1/J.DS&>VBU*R\)^*WN;-G95(F
MC2>%B,=)5(/-CU.K-JM.MA*4J4N:,
M:Z3=FM5"3ZI=T3>'=$T;7/\ @I=\0+?6M)TW6(+7X)Z7=V\&IV-M?PP77_")
M>!;3[1%%=1NB3?9;NZBW@9V7$BYPYR59SI\-8?V"1K+XN^&WLV>*-VLW
M>\\#0.]J64FW=H6:,M'M)5BIX.*]?$MKB'+;-J]"5_NJ/7YGGT4O[(QFGPU8
MV\M8+Y'L4UI:VGCO_@EY]EMK>V\_PEX3NI_(ACA\ZYFN?#K37$WEJ/,G\">(M.UR]\(?$#P;H'Q.L-.F\RY\.0R:G?&"TU-24,+OK^EV4.!YF3&Z
MD8R5\WA[#5*.98:I7I.$:U*I*BY+2?NJ[CZ1;9V9M6A/!UH4IJ3I5(1J);QU
M>C[>\D=-;V?[/^E^//V33-;ZO9?&)_A/8K\+8_"L7D^'[G3#X6F:==?^PJ$E
ML7$VHE#*VQA),6."YK*^82P^;-%
M+^QZ[DE[3ZPK][^[\]K_ (GT/X1TLZQ^WI^SW:^,M.L]3U ?LX^#[C5[74[2
MUO81K=O\)]:EGF>"1'A\^*_5G5E!"NH9", UY]67)D&8.C)QBL9447%M>ZZ\
M4E?>S1V4X\V:X55$FUAX732^)4GTVT9Y;\-O#GAY_P!G_P#X*#7[Z%H[WVF^
M*9;33;Q],LVN=.M;?7-7E@MK&9H2]G!'(JLJ0E%!52!\HQU8FI4681^J7[%))_98^"V221X4=
M1N))"IJ^IJHR>RJ .P Z5\KG6F:8W_ *^?^VQ/=RW_ ''#?X/U9]25Y9W"
M'H1[?3]:'MV#;Y=#'US1K/7M(O\ 1M0B,UE?VTMO.A8A@'0J)(WW966-MKHP
M/RNBL.1FO,S++X9C@<3@:L>:->G4BG=JTITY4UHI1V4F_B2]-U,X1JTITY*W
M-%QLO-6Z6[GY\ZEX6\0_#OQ!-IFI0W2V+SM_9NH;6:SOX'?]TT4P#)YAB4%X
MBQ9#E6'&3_/^*R?'\/9I4H5J7L\/*-,R+&^XYQA0N_."0!
MU/'6NS$P^L4%"UZEK);:\K5NBW9BG?:^VIY-:E-
M-SY?=CJW=;*[>E[Z+L7?@#X(\1>)OB'H5]86%R=-TG44U#5-4>/&GP)!D-;3
MRR I)),S"(VZ'S&5W(7",5_3>'L)4CCL).G"]"C*D[W7V*E-[-\WP_Y:LZEQJMKIT&UG5
M"K7-T[&2YNI0229)9F=N2AY[XT\&:OX
MG\>+Y L[329_A]?Z1-EI?T*4X);VMTLQE[X*UZR\2?#BR\/ZK?V%CX;\':]HUQKTUE::DS%6
M\-6]M#=I=((UN+FWLYI Z@8-L0 1G.\?9.,E)\O+K%:ZO1)75K>ZV[O32W5&
M5:QR-MX4\87?PO\$> O[.DCN-0U_59O$LFI
MK=6UI#HVFZ]JVN+!J9M&\VV_M.;^SXU6(JQCF=5(' 7[M;=-M]_T^9:JM=4F
M_1;?+0N7?AOQMJ?@'P?X6N[>:#7/#'C[1],N-2;3X]1M)='T:>X6R\2+;W95
M+W3_ .S7M2PDP2Z2(V'4D2Y735K7T] =1ZKRL_3[A(/ 6L/X%\$Y+O4[2QLE6"WCBM(+EI/)9P&M)&+9R*M>SBHZ
MZQ79[JUO(SYVO*VQ#X+T/Q]_PL71_$WBJTU!(M,\*:OX59D026\HT,:(L.H-
MY>Y?,U74)]9FB'RLT3ZS;^(+"&.[DU+1[6X5KOPQ)JL3#RX4L;?38K,F/;M;4SYO(J3070],FLI
MK3PSJOP^O]7\41>.KC6[KQ4UK+;:=)9OKUQ?V_BA?$T6U1+#IDD,::4)-[-"
M+9HA S$ ?@68]+U6S^)_BN^GL=;33]1\1^';FR>#P;::S8WMO;:'HUK+(=:]\8O[,AFLY/$'@+P[I/A[46S!;RZI!8^+(76"?&%>"6]L]Q'
MW/-4T+2WD'X6*?@D::VHZ#)IGPQU/PY-X:\*W=CJNJWVE2Z'+;W'E62KH.G0
MQ;$\4&:>":8SDR0Q^4LB2>;G4:TMTL8G@'0?'6A>+K+Q5J^F*EOX_75G
M\306OVR2\TBZE9]7\/-JL,^5MQ96H?2LQ#:#*!(2VW"V+;5K;6V.N^&USJ&F
M:5>^';_P]X@@U!=;\::@DUWI]Q;Z5<0WWB'5-2L0NK,GEYGMKJ':5!(W'*[E
M(IW^5C/D2^UMY'!_#+1M1TWQ5H-I#X;UZUL-*TC6;>^E\2:#;:;>>&VGDCEA
ML+3Q-IWV:#QG!7[.)6@A+[,;O*3/W16M'
M%XG"IPH/EB]_A?EM)/LC&>'A4DG-7Y?7]&NX[PI\-/A]X!:X;P/X&\)^$7O
M$O)/#F@:5HTER@*D)/)86T33("B$*Q(!4'&:=7%8BNH^UJ-\MM+))6\DDM+[
MVN52P]"DW*,.5ZV=Y?JV=KL/I^O_ ->L;O\ F_ WNNP!,$<="._I^-%W_-^
MKKL2TA!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %&WR#;Y'BWQ@^ 'PL^
M.UOH=I\3O#;^((/#"8-)MO#NK+JFJ0QVD6B3W,^EB738;M+.\DMY+N9DDN+>5URF&
M'E1[-5F&*C1J8=22IU7)R7+'>:M+7EOMV:\C%X2DJ].K%6]G&*6^\9777I^(
M_P")_P"SK\)?C#K_ (5\3_$#PR^M:SX,??H%TFK:MIWV;_3;?4!'/%IE[;I>
M1"\M89 DXD'WUP%ED#S1QV)PL)4J,N6$KW5H]4D_B3:T2V'6P=&O*,IK6+76
M71MK9KN/F_9Z^$\WQ=@^.C^%4/Q,M[<6T>NC4M3$.%TEM#29M)-W]@:[72F^
MSK'A.,U'
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MJ$N=1Y8_%=N][7WD]+V-5A:,:[Q*C:M*/*W=[))
M6M>W1=#B-+_9,^!.C?#?Q5\)=/\ "-Q!X$\9ZQ;:]XBT@^(?$,DE[JEG+836
M]PNHRZFUW:A)-,LCYZV1LR?LU_!^34?A/JC^&K@WOP1L;/3?AO)
M_;NN!=#M+ VK6L^'E[/7"I*GJ_=2M;KKMUN3P_LY?!Z)/BO#)X1BN[?XV7O\
M:/Q(MK_4-3O;?7+U9[VZBN88;B\==)EANK^XGB:P%L8I?+DC*O$C*GF.,_V2
MU;E>!7+1:23@M%:Z7O:))\U[K3JQK!X=>W7L[K$N]1-MW>O=Z6;NK6L,/!WAW46\26NG2:/I>J>(/$.L>(9M#TN57CEL=%CU.[DCT^)H
M7>+8(Y)(PX2617TQ6;8[&4O8UJD53NI.,(1AS26SERI.36^O77HC.AE^&
MPL_:4H/G2LG*3ERKM&[T^1@ZE^Q#^SAJOC2Y\<7?@>7[;>Z[%XEO]#@US6+;
MPC>Z[%(\RZA(K+('TCG>94Z"H1KKEC'D4G&+J
M*&W*IM9J'-W]K%[F#0/BY>R:AX\LSK^O2/JUW)--.\D-U)J+3:8/-N)6"V:YI:O[]/E8]
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M#^E ./\YZ_6@ Z?A0 4 % !0 A /'/X$CMCJ#0 ?YSC XSTX':@ P,@X
MY'3VQZ>E "T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 (3@$] !GZ8H ;YBX
MXW$#T1VQCZ*>: &F:-02=ZA1GF*48 ]ME $7VRWP3O8!?6*48P,]"E ##J-F
M!_K2 /\ IE-QC_MG0ET#;Y$1U?3TZSE%@/^0H !SS9Z@ /^W2A8>KMR?C'_,",^/O"*@G
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MU/$+_EW;_MZ/_P D&WD1'XY?"M.OBR) /8:71]0Q7_/K_P FA_\ )!>WE8C_ .&@_@[@G_A-
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M?]03Q/V_[@E5_9N-7_+G;^_3_P#DB?;4_P";\'_D,/[5'P"4G_P#)A[:DOM6MY/\ R(Q^UM^SQC/_ LFQP/^H'XI
M&,>QT*C^R*N,?]
MP*C^R4O\AI_;"_9N4$_\+/T\!1G_D!^*^ /
M^X#1_9.8?] __D]/_P"3#ZS0_G_"7^1%_P -D?LU#_FJ.GC'_4"\6\8_[@%'
M]DY@O^8?;_IY3_\ DP^LT5]O;RE_D-/[9?[-"@D_%*P 49/_ !(/%W '7_F7
MZ%E.8;?5_P#R>G_\F'UF@OMVM_=E_D0_\-I?LQC_ )JKIXQ_U+_C 8Q_W+U5
M_8^8K_F&V_Z>4O\ Y,CZYAE_R\LE_=E_\B,/[:W[+ZCGXKZQ
M\/5/]DY@O^8>W_;]/_Y,7U["?\_?_)9__(D?_#;?[+8'_)6=- '_ % /&'&/
M^Y=H_LG,/^@?_P GI_\ R8?7L+_S]_\ )9__ "(W_AM_]ED?\U;TT8_ZE_QB
M,8_[EVFLHS#1+#^G[RE_\F+Z_A%_R]M;^[/_ .1&']N+]E903_PMS3 %&?\
MD7_&/&/8>':K^Q\9C&!D\?\(YZ4UDF9[?5O_*E+_P"6 LQP>RK?^23_ /D2(_MV
M?LGJ"?\ A?[)7_ $6/3/\ PG/&W_S,T?V%FO\ T"_^5*/_ ,L#^U,!
M_P __P#R2I_\@'_#>?[)7_18],_\)SQM_P#,S1_86:_] O\ Y4H__+ _M3 ?
M\_\ _P DJ?\ R ?\-Y_LE?\ 18],_P#"?[)7_ $6/3/\ PG/&W_S,T?V%FO\ T"_^5*/_
M ,L#^U,!_P __P#R2I_\@'_#>?[)7_18],_\)SQM_P#,S1_86:_] O\ Y4H_
M_+ _M3 ?\_\ _P DJ?\ R ?\-Y_LE?\ 18],_P#"?[)7_ $6/3/\ PG/&W_S,T?V%FO\
MT"_^5*/_ ,L#^U,!_P __P#R2I_\@'_#>?[)7_18],_\)SQM_P#,S1_86:_]
M O\ Y4H__+ _M3 ?\_\ _P DJ?\ R ?\-Y_LE?\ 18],_P#"?[)7_18],_\)SQM_P#,S5?Z
MOYNO^83;_I[1_P#E@?VK@%_R_P!O[E3_ .0/=?AC\7/AU\9= N_$_P ,_$L'
MBG0;#5[C0;O4+>RU2P2'5K6RT_4)[,PZM8VLS,EGJEA)O6-D(N Q96"^?B<
M)B,%45+$4_9S<>9+FC+2[2=XN2WBUO?0Z*&*P^(@YT:G-"+Y6[2CJDG:TDGL
MUY'H]-248QQ+:>_K9'FCVLUY6#;RL0?\ "MM"
MP5^UZN >,">S'7CH+&CVLU\@V^1"WPNT HP-YK&"I!Q<6@X(P>MB>WL::JR3
M72P;?(I?\*C\-N#_ *9K2CH1]IL/Q_YAGH:T>(J1[?6GD/]"N_P3\+$X_M#7P,8.+G3@
MGH5-9A6MT5O(-OD5G_9?\!,0/[7\78QCC4-&&.O0'0#S2_M&MV7X?Y!^A"_[
M*WP^;_F,^,NF,?;]#/KV_P"$>JEF->+2LNG0-O*Q7/[*?PZ'R'6?&B[N/DO]
M!4#/'?P[UK7^T<1_=5O(6B\K#&_9(^'.TC^W/&_0C_D(Z!Z?]BU0LQQ"_ET_
MNB>D7Y)E0_L@?#9QSKOCE>-N%U+0 ,?CX9Z\T_[0Q']U6\C!)>EB(_L.\8Q_P A30?_ )FJ/[0Q"_ET\AV2[Z%5OV,?A>Y'_$^\?*, 875/#P'7
M_:\+L^( XQ_R%O#PQU_ZE:A9CB%_+I_
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M\8/BCXH $8PNM>%5Q_T)?6C^UL7T<5;^Z@^KP7E8B/_!.OX)X(_P"$H^*0
MXQ_R'/"QQV_Z$RC^UL6NL=/[J#ZO!=]/Z[D!_P""C^UL6
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M_P"1O^+ZX&.->\%G&._S> #2_P!8\ W%;^ZC)9?12W>GK_ /)$3?\ !+/X
M ,"#XQ^,.",?\A[P2.#QV^'M"XBQZ:^#1K[*%_9U)Z7M?3K_ )D!_P""5/[/
MA!_XK'XQ*,$$#7_!73'/)^'W'%;+B/,/^G?_ (")911T]]_34+-/^AR^,O\
MX/\ P1_\[ZC_ %CQ_P#T[_\ 0_L+#_SO[G_ /)A_P .HOV>/^AR^,O_ (/_
M 1_\[ZC_6/'_P#3O_P$/["P_P#._N?_ ,F'_#J+]GC_ *'+XR_^#_P1_P#.
M^H_UCQ__ $[_ / 0_L+#_P [^Y__ "8?\.HOV>/^AR^,O_@_\$?_ #OJ/]8\
M?_T[_P# 0_L+#_SO[G_\F'_#J+]GC_H/\
MH/^AR^,O\ X/\ P1_\
M[ZC_ %CQ_P#T[_\ 0_L+#_SO[G_ /)A_P .HOV>/^AR^,O_ (/_ 1_\[ZC
M_6/'_P#3O_P$/["P_P#._N?_ ,F'_#J+]GC_ *'+XR_^#_P1_P#.^H_UCQ__
M $[_ / 0_L+#_P [^Y__ "8?\.HOV>/^AR^,O_@_\$?_ #OJ/]8\?_T[_P#
M0_L+#_SO[G_\F'_#J+]GC_H/\ J/\ @CM_W3ZA<1Y@FOX>G]T/["P_\[^Y_P#R
M8#_@E%^SN/\ F-GSOW>EGT_[
M?/L3]GS]GWP;^S9X,U/P+X%U/Q-JFD:IXGO?%EQ<>*KS2K[4$U&^TK1='EAA
METC1M-A6R6VT*T94:!W#R3$R%658_(QF,JX^K&K74>>,%%T;VOT2ZM]D?_9
end5>77w>
XML
9
infi-20200730_htm.xml
IDEA: XBRL DOCUMENT
0001113148
2020-07-30
2020-07-30
false
0001113148
8-K
2020-07-30
Infinity Pharmaceuticals, Inc.
DE
000-31141
33-0655706
1100 Massachusetts Avenue
Floor 4
Cambridge
MA
02138
617
453-1000
false
false
false
false
Common Stock, $0.001 par value
INFI
NASDAQ
false
XML
10
R1.htm
IDEA: XBRL DOCUMENT
v3.20.2
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
EXCEL
11
Financial_Report.xlsx
IDEA: XBRL DOCUMENT
begin 644 Financial_Report.xlsx
M4$L#!!0 ( &:8_E '04UB@0 +$ 0 9&]C4')OQLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQJ=0U[R;UEA_6\#MI7E!+ P04
M " !FF/Y0!+-;->T K @ $0 &1O8U!R;W!S+V-O&ULS9+!
M2L0P$(9?17)O)VE!,71S43PI""XHWD(RNQMLTI",M/OVIG6WB^@#>,S,GV^^
M@>E,E&9(^)R&B(D25M-&F9@%5S18Z ,HA; U#PQ
M'J>^@PM@AA$FG[\+:%?B4OT3NW2 G9)3=FMJ',=Z;)=&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%[R:0S>IU].LYKE']I
MJP&G[;N;SY/\3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/FE1M'V5;SOX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
MC
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?!
M8/+]U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @
M9IC^4*Q3>UU$! UA !@ !X;"]W;W)KM'.)+%E V%W"#.$)%NZFRP-M#O33B^$+8,FMN1*^!%^[#;75AP(NSG(KTBH7]! C_P
M_QGN 4&%$5080:D78ACDC_'26 T3]22Q3;G33W$
MPP>7GQ"(;@71/0]BQK50,;F7,8%Y:N3!E0XC_MV[=RUCWJO8>JCBO;3";LDS
M7PDWZ@#YQ+)&,EQG*A,AG=)LS6"=1+RP(F*IN2!3&5TAH/T*M'\.**@IG2O-
MW'*^(',+XTB4)A-52*NW$:ON]?
MAI1V*Q+5 ?:$VLA$-EYNP;*E%O$+'KC9V&GP37+5L
M9UJ]"ADU3G:+YN,80ZL+!,4M_M]H,V4L2\GO(C_I)2V*?D## <96UPV*VWTY
MAV/89YU&P07Z]!H#J8L$Q=W]LP(O!VM7$K.V%I%N+[R$%8I5+5I7 XH[]E/5>IB(05?PCI\(Y]X\_C@4N#PE-*0=AMK
MH'=T2G4G_D?FIL60E">@YE]=@[C>':)W#:OR\N"Z5!:.P>7MFC.P"?&.PM7_\H8_0U02P,$% @ 9IC^4(.II0/4 0 ,@8 T !X;"]S
M='EL97,N>&ULU57;BM1 $/V5IC_ GD1V04D"*BP(*@L[#[YVDDK2T#J3YV^3M;C).&I T R*JG[G':(]BUC?=6!XOTK8T'[
M3&.5&;0F-,39476&+TSKVDD
M?"E70"Y.;E,;5X+8V"5VI(I/0!#M.M%WXHK$L)!&-\D$M><GSVL(Y; RU8@Y5/8
MPJ_-E?;8D+@7'^NP#21,=0V]H26,,A$$_:-:U#[(WOV1++'B8O#]X&>C9_QM
M, B/#AHQSGALMOZWU)/;ZMQ:.;V3HM4*XMQ_N6&1\74PQ6]
MNJ ;2\)#F-,OX7V5NP=2#D*BT OJ1%V#?G%/O3SRTC_@5_J^OH:Q+/6S*G
M>_P9:C&H-UO58UB7I6J//X7W*+F?&^[_$L4/4$L#!!0 ( &:8_E"7BKL<
MP !," + 7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$
M^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+-8?20$3;8T.P6BP^0"X99K>]9!:G%C:^?VZH:TE[VE-S9NMQ=%A?BTX'H
ME'QY%V)N:I%FGJ:QJ,';>$X1+_)UW,#ECQ ,ZE._CR#
M+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HDO\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0 ( &:8_E D'INB
MK0 /@! : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,
MA:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@
MMO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<
M//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P
M6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04 " !FF/Y0
M99!YDAD! #/ P $P %M#;VYT96YT7U1YO,^>EZS>CQ&P
MZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5
M,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*I
ML0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U
M[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_
M 5!+ 0(4 Q0 ( &:8_E '04UB@0 +$ 0 " 0
M !D;V-0&UL4$L! A0#% @ 9IC^4 2S6S7M *P(
M !$ ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#%
M @ 9IC^4)E&PO=V]R:W-H965T&UL4$L! A0#%
M @ 9IC^4(.II0/4 0 ,@8 T ( !A@P 'AL+W-T>6QE
M&PO=V]R:V)O;VLN>&UL4$L! A0#% @
M9IC^4"0>FZ*M ^ $ !H ( !SA 'AL+U]R96QS+W=O
M9(9 0 SP, !,
M ( !LQ$ %M#;VYT96YT7U1Y
XML
12
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
13
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
..report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
..report table.authRefData a {
display: block;
font-weight: bold;
}
..report table.authRefData p {
margin-top: 0px;
}
..report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
..report table.authRefData .hide a:hover {
background-color: #2F4497;
}
..report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
..report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
..pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
..report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
..report hr {
border: 1px solid #acf;
}
/* Top labels */
..report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
..report th.void{
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
..report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
..report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
..report td.pl div.a {
width: 200px;
}
..report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
..report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
..report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
..report .re, .report .reu {
background-color: #def;
}
..report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
..report .ro, .report .rou {
background-color: white;
}
..report .rou td {
border-bottom: 1px solid black;
}
..report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
..report .fn {
white-space: nowrap;
}
/* styles for numeric types */
..report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
..report .nump {
padding-left: 2em;
}
..report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
..report .text {
text-align: left;
white-space: normal;
}
..report .text .big {
margin-bottom: 1em;
width: 17em;
}
..report .text .more {
display: none;
}
..report .text .note {
font-style: italic;
font-weight: bold;
}
..report .text .small {
width: 10em;
}
..report sup {
font-style: italic;
}
..report .outerFootnotes {
font-size: 1em;
}
XML
14
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.20.2
html
1
95
1
false
0
0
false
0
false
false
R1.htm
0001001 - Document - Cover
Sheet
http://www.infi.com/role/Cover
Cover
Cover
1
false
false
All Reports
Book
All Reports
infi-20200730.htm
infi-20200730.xsd
infi-20200730_cal.xml
infi-20200730_def.xml
infi-20200730_lab.xml
infi-20200730_pre.xml
pressrelease2020q210q.htm
http://xbrl.sec.gov/dei/2019-01-31
true
true
JSON
16
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"instance": {
"infi-20200730.htm": {
"axisCustom": 0,
"axisStandard": 0,
"contextCount": 1,
"dts": {
"calculationLink": {
"local": [
"infi-20200730_cal.xml"
]
},
"definitionLink": {
"local": [
"infi-20200730_def.xml"
]
},
"inline": {
"local": [
"infi-20200730.htm"
]
},
"labelLink": {
"local": [
"infi-20200730_lab.xml"
],
"remote": [
"https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
]
},
"presentationLink": {
"local": [
"infi-20200730_pre.xml"
]
},
"referenceLink": {
"remote": [
"https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
]
},
"schema": {
"local": [
"infi-20200730.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
"http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd"
]
}
},
"elementCount": 24,
"entityCount": 1,
"hidden": {
"http://xbrl.sec.gov/dei/2019-01-31": 2,
"total": 2
},
"keyCustom": 0,
"keyStandard": 95,
"memberCustom": 0,
"memberStandard": 0,
"nsprefix": "infi",
"nsuri": "http://www.infi.com/20200730",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "infi-20200730.htm",
"contextRef": "i704efe2b73bc42ba8bb2805ac79409c8_D20200730-20200730",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "0001001 - Document - Cover",
"role": "http://www.infi.com/role/Cover",
"shortName": "Cover",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "infi-20200730.htm",
"contextRef": "i704efe2b73bc42ba8bb2805ac79409c8_D20200730-20200730",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 0,
"tag": {
"dei_AmendmentFlag": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag",
"terseLabel": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code",
"terseLabel": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CoverAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Cover page.",
"label": "Cover [Abstract]"
}
}
},
"localname": "CoverAbstract",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"xbrltype": "stringItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
"label": "Document Period End Date",
"terseLabel": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "dateItemType"
},
"dei_DocumentType": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type",
"terseLabel": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address, Address Line One",
"terseLabel": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressAddressLine2": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Address Line 2 such as Street or Suite number",
"label": "Entity Address, Address Line Two",
"terseLabel": "Entity Address, Address Line Two"
}
}
},
"localname": "EntityAddressAddressLine2",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address, City or Town",
"terseLabel": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address, Postal Zip Code",
"terseLabel": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address, State or Province",
"terseLabel": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r5"
],
"lang": {
"en-US": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key",
"terseLabel": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r5"
],
"lang": {
"en-US": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company",
"terseLabel": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number",
"terseLabel": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation, State or Country Code",
"terseLabel": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r5"
],
"lang": {
"en-US": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name",
"terseLabel": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r5"
],
"lang": {
"en-US": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number",
"terseLabel": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "employerIdItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number",
"terseLabel": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_PreCommencementIssuerTenderOffer": {
"auth_ref": [
"r2"
],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
"label": "Pre-commencement Issuer Tender Offer",
"terseLabel": "Pre-commencement Issuer Tender Offer"
}
}
},
"localname": "PreCommencementIssuerTenderOffer",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_PreCommencementTenderOffer": {
"auth_ref": [
"r3"
],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
"label": "Pre-commencement Tender Offer",
"terseLabel": "Pre-commencement Tender Offer"
}
}
},
"localname": "PreCommencementTenderOffer",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r0"
],
"lang": {
"en-US": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Title of 12(b) Security",
"terseLabel": "Title of 12(b) Security"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "securityTitleItemType"
},
"dei_SecurityExchangeName": {
"auth_ref": [
"r1"
],
"lang": {
"en-US": {
"role": {
"documentation": "Name of the Exchange on which a security is registered.",
"label": "Security Exchange Name",
"terseLabel": "Security Exchange Name"
}
}
},
"localname": "SecurityExchangeName",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "edgarExchangeCodeItemType"
},
"dei_SolicitingMaterial": {
"auth_ref": [
"r4"
],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
"label": "Soliciting Material",
"terseLabel": "Soliciting Material"
}
}
},
"localname": "SolicitingMaterial",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_TradingSymbol": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol",
"terseLabel": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "tradingSymbolItemType"
},
"dei_WrittenCommunications": {
"auth_ref": [
"r6"
],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
"label": "Written Communications",
"terseLabel": "Written Communications"
}
}
},
"localname": "WrittenCommunications",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.infi.com/role/Cover"
],
"xbrltype": "booleanItemType"
}
},
"unitCount": 0
}
},
"std_ref": {
"r0": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b"
},
"r1": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "d1-1"
},
"r2": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "13e",
"Subsection": "4c"
},
"r3": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "14d",
"Subsection": "2b"
},
"r4": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "14a",
"Subsection": "12"
},
"r5": {
"Name": "Regulation 12B",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2"
},
"r6": {
"Name": "Securities Act",
"Number": "230",
"Publisher": "SEC",
"Section": "425"
}
},
"version": "2.1"
}
1万+
被折叠的 条评论
为什么被折叠?
到【灌水乐园】发言
